According to a published report in the Wall St. Journal, Glaxo Smith Kline became the latest drug manufacturer to add a warning label to its ADHD drug, Dexedrine. The new warning label will include a warning about cardiac risks and psychiatric side effects. The new warning was posted on the FDA website yesterday.